Go Pro
→ Trump’s secret China deal (From Porter & Company) (Ad)tc pixel Free IMA Stock Alerts

ImageneBio (IMA) Financials

ImageneBio logo
$6.11 +0.20 (+3.38%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$5.85 -0.26 (-4.26%)
As of 07/13/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ImageneBio

Annual Income Statements for ImageneBio

This table shows ImageneBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -44 -34 -69 -68 -48 -52
Consolidated Net Income / (Loss)		 -44 -34 -69 -68 -37 -45
Net Income / (Loss) Continuing Operations		 -44 -34 -69 -68 -37 -45
Total Pre-Tax Income 		-44 -34 -69 -68 -37 -46
Total Operating Income		 -45 -34 -71 -75 -37 -48
Total Gross Profit		 9.19 31 16 9.16 3.50 0.80
Total Revenue		 9.19 31 16 9.16 3.50 0.80
Operating Revenue		 9.19 31 16 9.16 3.50 0.80
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 54 65 87 85 41 49
Selling, General & Admin Expense		 8.87 18 22 25 8.39 21
Research & Development Expense		 45 47 64 60 32 29
Total Other Income / (Expense), net		 0.26 0.05 2.14 7.09 0.45 2.75
Interest & Investment Income		 - 0.02 2.15 7.11 0.37 2.04
Other Income / (Expense), net		 0.26 0.02 -0.01 -0.02 0.07 0.72
Income Tax Expense		 - - 0.00 -0.16 0.01 -0.35
Preferred Stock Dividends Declared		 - - - - 12 7.05
Basic Earnings per Share		 ($16.00) ($1.22) ($1.90) ($1.63) ($66.30) ($9.64)
Weighted Average Basic Shares Outstanding		 2.77M 27.98M 36.19M 41.74M 3.38M 4.87M
Diluted Earnings per Share		 ($16.00) ($1.22) ($1.90) ($1.63) ($66.30) ($9.64)
Weighted Average Diluted Shares Outstanding		 2.77M 27.98M 36.19M 41.74M 2.19M 0.00

Quarterly Income Statements for ImageneBio

This table shows ImageneBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -17 -19 -16 -14 -6.18 -9.12 -9.13 -2.77 -26 -15 -11
Consolidated Net Income / (Loss)		 -17 -19 -16 -14 -3.18 -9.12 -6.08 -2.77 -25 -9.18 -11
Net Income / (Loss) Continuing Operations		 -17 -19 -16 -14 -3.18 -9.12 -6.08 -2.77 -25 -9.18 -11
Total Pre-Tax Income 		-17 -20 -16 -14 -3.18 -9.07 -6.08 -2.75 -25 -9.50 -11
Total Operating Income		 -20 -22 -18 -16 -2.04 -13 -6.00 -8.75 -27 -2.31 -12
Total Gross Profit		 1.19 0.66 0.00 0.00 3.50 - 0.80 0.00 0.00 0.80 0.00
Total Revenue		 1.19 0.66 0.00 0.00 3.50 - 0.80 0.00 0.00 0.80 0.00
Operating Revenue		 1.19 0.66 0.00 0.00 3.50 - 0.80 0.00 0.00 0.80 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 21 23 18 16 5.54 13 6.80 8.75 27 3.11 12
Selling, General & Admin Expense		 6.03 8.29 6.00 5.31 1.65 7.60 2.76 4.42 11 -0.37 6.12
Research & Development Expense		 15 14 9.65 9.83 3.89 4.58 4.04 4.03 16 5.23 5.96
Total Other Income / (Expense), net		 2.16 2.26 2.11 2.16 -1.15 3.45 -0.08 6.00 1.74 -7.19 1.47
Interest & Investment Income		 2.16 2.27 2.11 1.92 0.05 1.57 -0.08 1.29 -0.10 -0.58 1.13
Other Income / (Expense), net		 -0.00 -0.01 -0.01 0.24 -1.19 1.88 -0.01 4.71 1.84 -6.61 0.34
Income Tax Expense		 0.00 -0.16 0.03 0.06 0.00 0.05 0.00 0.02 -0.07 -0.32 0.01
Preferred Stock Dividends Declared		 - - - - 3.00 - 3.05 - 0.85 - 0.00
Basic Earnings per Share		 ($0.40) ($0.40) ($0.33) ($0.28) ($2.58) ($0.20) ($3.80) ($0.06) ($2.91) ($3.16) ($0.95)
Weighted Average Basic Shares Outstanding		 43.44M 41.74M 48.26M 48.26M 1.40M 48.26M 3.81M 48.26M 8.53M 4.87M 22.42M
Diluted Earnings per Share		 ($0.40) ($0.40) ($0.33) ($0.28) ($2.58) ($0.20) ($3.80) ($0.06) ($2.91) ($3.16) ($0.95)
Weighted Average Diluted Shares Outstanding		 43.44M 41.74M 48.26M 48.26M 0.00 48.26M 4.81M 48.26M 0.00 0.00 22.42M
Weighted Average Basic & Diluted Shares Outstanding		 48.26M 48.26M 48.26M 48.26M 48.26M 48.26M 48.26M 48.26M 11.18M 0.00 11.28M

Annual Cash Flow Statements for ImageneBio

This table details how cash moves in and out of ImageneBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 81 70 -172 60 -3.20 82
Net Cash From Operating Activities		 -38 -60 -74 -80 -21 -48
Net Cash From Continuing Operating Activities		 -38 -60 -74 -80 -21 -48
Net Income / (Loss) Continuing Operations		 -44 -34 -69 -68 -37 -45
Consolidated Net Income / (Loss)		 -44 -34 -69 -68 -37 -45
Depreciation Expense		 0.30 0.54 0.75 1.02 1.14 0.40
Amortization Expense		 - 0.00 0.05 -2.02 0.39 0.56
Non-Cash Adjustments To Reconcile Net Income		 14 6.35 8.99 11 15 16
Changes in Operating Assets and Liabilities, net		 -7.77 -33 -15 -22 -1.52 -19
Net Cash From Investing Activities		 2.92 -1.76 -99 64 11 -5.81
Net Cash From Continuing Investing Activities		 2.92 -1.76 -99 64 11 -5.81
Acquisitions		 - - - - 0.00 -5.22
Purchase of Investments		 - 0.00 -216 -90 0.00 -10
Sale of Property, Plant & Equipment		 - - - 0.00 0.97 0.00
Sale and/or Maturity of Investments		 - 0.00 118 155 10 9.80
Net Cash From Financing Activities		 116 132 1.10 76 6.91 135
Net Cash From Continuing Financing Activities		 116 132 1.10 76 6.91 135
Issuance of Debt		 - - - - 7.50 15
Issuance of Common Equity		 -0.06 131 0.00 37 0.00 71
Other Financing Activities, net		 0.07 0.58 1.10 39 -0.59 49
Effect of Exchange Rate Changes		 - - - - 0.09 0.60
Cash Income Taxes Paid		 - - - - 0.22 0.02

Quarterly Cash Flow Statements for ImageneBio

This table details how cash moves in and out of ImageneBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 51 -1.38 -67 -8.58 69 -5.80 -7.20 22 72 -8.63 -18
Net Cash From Operating Activities		 -20 -22 -18 -13 13 -6.26 -7.23 -3.42 -27 -7.22 -15
Net Cash From Continuing Operating Activities		 -20 -22 -18 -13 13 -6.26 -7.23 -3.42 -27 -7.22 -15
Net Income / (Loss) Continuing Operations		 -17 -19 -16 -14 -1.88 -9.12 -6.08 -2.77 -27 -6.91 -11
Consolidated Net Income / (Loss)		 -17 -19 -16 -14 -1.88 -9.12 -6.08 -2.77 -27 -6.91 -11
Depreciation Expense		 0.24 0.31 0.22 0.09 0.81 0.09 0.00 0.09 -0.17 0.39 0.00
Amortization Expense		 -0.58 -0.31 -0.39 -0.42 1.13 -0.29 0.08 -0.05 0.68 0.13 0.17
Non-Cash Adjustments To Reconcile Net Income		 2.47 4.06 3.29 1.74 10 1.52 0.18 1.00 13 0.05 0.88
Changes in Operating Assets and Liabilities, net		 -4.79 -6.38 -5.27 -0.18 2.68 1.54 -1.41 -1.69 -13 -0.88 -5.22
Net Cash From Investing Activities		 32 20 -49 3.92 56 0.46 0.00 25 -37 -1.36 -0.44
Net Cash From Continuing Investing Activities		 32 20 -49 3.92 56 0.46 0.00 25 -37 -1.36 -0.44
Purchase of Investments		 -18 -25 -62 -9.97 72 -7.26 0.00 -6.00 22 -8.91 -11
Sale and/or Maturity of Investments		 50 45 14 14 -17 15 0.00 46 -69 7.55 10
Net Cash From Financing Activities		 39 0.06 0.00 - - - 0.03 - 135 - -3.24
Net Cash From Continuing Financing Activities		 39 0.06 0.00 - - - 0.03 - 135 - -3.24
Repurchase of Common Equity		 - - 0.00 - - - -0.02 - - - 0.00
Other Financing Activities, net		 39 0.06 0.00 - - - 0.05 - 49 - -3.24
Effect of Exchange Rate Changes		 - - - - - - 0.00 - - -0.05 0.00
Cash Income Taxes Paid		 - - - - - - 0.00 - - 0.01 0.00

Annual Balance Sheets for ImageneBio

This table presents ImageneBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 168 248 172 192 16 153
Total Current Assets		 166 237 160 179 12 140
Cash & Equivalents		 162 232 60 120 12 95
Short-Term Investments		 - 0.00 97 56 0.00 41
Prepaid Expenses		 3.48 4.30 3.06 3.20 0.35 4.94
Plant, Property, & Equipment, net		 1.39 2.44 3.21 2.34 0.00 0.00
Total Noncurrent Assets		 0.17 8.92 9.04 11 3.45 13
Noncurrent Note & Lease Receivables		 - - - - 0.00 7.02
Other Noncurrent Operating Assets		 0.17 8.92 9.04 11 3.45 5.67
Total Liabilities & Shareholders' Equity		 168 248 172 192 16 153
Total Liabilities		 63 40 25 22 17 20
Total Current Liabilities		 28 27 22 14 17 11
Accounts Payable		 2.12 2.38 2.09 2.07 5.29 1.44
Accrued Expenses		 5.40 5.85 8.34 8.58 3.46 7.53
Other Current Liabilities		 0.19 1.85 1.91 3.56 0.31 2.26
Total Noncurrent Liabilities		 35 13 3.79 8.13 0.24 8.60
Other Noncurrent Operating Liabilities		 0.00 5.14 3.79 7.18 0.24 8.60
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -101 208 147 170 -161 133
Total Preferred & Common Equity		 -101 208 147 170 -161 133
Preferred Stock		 0.00 0.00 0.00 0.00 19 0.00
Total Common Equity		 -101 208 147 170 -180 133
Common Stock		 10 353 362 452 2.16 363
Retained Earnings		 -111 -145 -214 -282 -180 -230
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.76 -0.05 -1.79 0.09

Quarterly Balance Sheets for ImageneBio

This table presents ImageneBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 215 173 157 149 131 126 161 137
Total Current Assets		 201 161 149 142 117 99 148 122
Cash & Equivalents		 121 53 44 45 37 58 103 76
Short-Term Investments		 76 104 101 93 77 37 39 41
Prepaid Expenses		 3.70 3.82 3.90 3.50 2.95 3.37 4.95 4.80
Plant, Property, & Equipment, net		 2.63 0.86 0.77 0.68 0.51 0.42 0.00 0.00
Total Noncurrent Assets		 12 11 7.39 6.77 13 27 13 15
Noncurrent Note & Lease Receivables		 - - - - - - 7.51 5.73
Other Noncurrent Operating Assets		 12 11 7.39 6.77 13 27 5.84 8.95
Total Liabilities & Shareholders' Equity		 215 173 157 149 131 126 161 137
Total Liabilities		 28 17 15 15 13 10 21 13
Total Current Liabilities		 19 10 8.20 9.24 8.79 7.32 11 6.63
Accounts Payable		 3.95 1.91 1.41 1.54 0.81 0.51 2.08 0.57
Accrued Expenses		 11 4.82 3.09 3.78 4.10 2.98 6.90 3.76
Other Current Liabilities		 3.47 3.44 3.70 3.92 3.89 3.83 2.16 2.31
Total Noncurrent Liabilities		 8.88 7.27 6.43 5.52 3.80 2.94 9.90 6.72
Other Noncurrent Operating Liabilities		 8.02 7.27 6.43 5.52 3.80 2.94 9.90 6.72
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 155 155 143 134 118 116 140 123
Total Preferred & Common Equity		 155 155 143 134 118 116 140 123
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 155 155 143 134 118 116 140 123
Common Stock		 419 454 455 456 458 459 363 364
Retained Earnings		 -263 -299 -312 -322 -340 -343 -223 -241
Accumulated Other Comprehensive Income / (Loss)		 -0.29 -0.31 -0.35 0.24 0.10 0.07 0.09 -0.02

Annual Metrics And Ratios for ImageneBio

This table displays calculated financial ratios and metrics derived from ImageneBio's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 35,906,794.00 36,257,493.00 48,258,111.00 - 11,181,672.00
DEI Adjusted Shares Outstanding		 0.00 2,992,233.00 3,021,458.00 4,021,509.00 - 11,181,672.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -11.40 -22.76 -16.95 - -4.69
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 237.01% -49.60% -41.35% -100.00% -77.14%
EBITDA Growth		 0.00% 23.63% -108.85% -9.03% 24.87% -32.11%
EBIT Growth		 0.00% 22.91% -107.87% -6.38% 25.16% -29.26%
NOPAT Growth		 0.00% 23.32% -107.70% -6.36% 21.80% -30.95%
Net Income Growth		 0.00% 22.91% -101.57% 0.87% 27.77% -24.01%
EPS Growth		 0.00% 92.38% -55.74% 14.21% 37.42% 85.46%
Operating Cash Flow Growth		 0.00% -59.29% -23.00% -7.60% 42.31% -124.42%
Free Cash Flow Firm Growth		 0.00% 0.00% -10.36% 9.35% 16.14% -54.40%
Invested Capital Growth		 0.00% 58.34% 59.01% 52.32% 154.83% 64.03%
Revenue Q/Q Growth		 0.00% 186.00% -48.60% -34.35% -100.00% 122.86%
EBITDA Q/Q Growth		 0.00% 46.30% -34.23% -10.12% 16.19% 22.29%
EBIT Q/Q Growth		 0.00% 45.83% -33.70% -10.00% 16.66% 18.00%
NOPAT Q/Q Growth		 0.00% 45.80% -33.79% -9.90% 13.74% 29.81%
Net Income Q/Q Growth		 0.00% 45.82% -32.57% -8.59% 17.39% 13.36%
EPS Q/Q Growth		 0.00% 90.18% -458.49% -1.24% 16.39% -63.67%
Operating Cash Flow Q/Q Growth		 0.00% -1.34% -6.14% -5.51% 25.27% 30.45%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.26% -6.02% 8.12% 23.33%
Invested Capital Q/Q Growth		 0.00% 42.91% 35.93% 46.49% 168.64% 19.67%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 100.00%
EBITDA Margin		 -478.09% -108.35% -448.92% -834.52% 0.00% -5,846.50%
Operating Margin		 -484.22% -110.18% -453.99% -823.33% 0.00% -6,056.38%
EBIT Margin		 -481.36% -110.10% -454.05% -823.57% 0.00% -5,966.75%
Profit (Net Income) Margin		 -481.36% -110.10% -440.29% -744.17% 0.00% -5,668.63%
Tax Burden Percent		 100.00% 100.07% 100.00% 99.76% 100.31% 99.23%
Interest Burden Percent		 100.00% 99.93% 96.97% 90.57% 86.94% 95.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -42.18% -21.81% -38.76% -43.04% -33.30% -68.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -1,864.63% 0.00%
Operating Return on Assets (OROA)		 -26.28% -16.39% -33.76% -41.41% 0.00% -56.52%
Return on Assets (ROA)		 -26.28% -16.39% -32.73% -37.42% 0.00% -53.70%
Return on Common Equity (ROCE)		 40.62% -7.45% -38.76% -43.04% -33.30% 24.29%
Return on Equity Simple (ROE_SIMPLE)		 43.80% -16.41% -46.79% -40.16% -39.10% 0.00%
Net Operating Profit after Tax (NOPAT)		 -31 -24 -50 -53 -41 -34
NOPAT Margin		 -338.95% -77.12% -317.79% -576.33% 0.00% -4,239.46%
Net Nonoperating Expense Percent (NNEP)		 -8.01% -5.17% -9.83% -9.28% -5.34% -16.34%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -30.93% -32.51% -25.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 96.43% 58.14% 142.15% 272.11% 0.00% 2,590.75%
R&D to Revenue		 487.79% 152.03% 411.84% 651.22% 0.00% 3,565.63%
Operating Expenses to Revenue		 584.22% 210.18% 553.99% 923.33% 0.00% 6,156.38%
Earnings before Interest and Taxes (EBIT)		 -44 -34 -71 -75 -56 -48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -34 -70 -76 -57 -47
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.17 0.66 0.56 0.63 0.58
Price to Tangible Book Value (P/TBV)		 0.00 2.17 0.66 0.56 0.63 0.58
Price to Revenue (P/Rev)		 13.60 14.53 6.18 10.38 0.00 96.44
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 18.33 7.04 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.01 0.01 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.01 0.01 0.00
Financial Leverage		 -1.56 -1.26 -1.10 -1.05 -1.01 -1.06
Leverage Ratio		 1.60 1.33 1.18 1.15 1.13 1.28
Compound Leverage Factor		 1.60 1.33 1.15 1.04 0.98 1.23
Debt to Total Capital		 0.00% 0.00% 0.00% 0.56% 0.84% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.56% 0.84% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 196.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -96.30% 100.00% 100.00% 99.44% 99.16% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.01 -0.02 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 2.28 2.15 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.01 -0.02 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.02 -0.03 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 3.31 2.99 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.02 -0.03 0.00
Altman Z-Score		 0.42 6.62 0.24 0.27 -0.56 0.22
Noncontrolling Interest Sharing Ratio		 196.30% 65.85% 0.00% 0.00% 0.00% 135.25%
Liquidity Ratios		 - - - - - -
Current Ratio		 5.86 8.70 7.44 12.58 11.80 12.49
Quick Ratio		 5.74 8.54 7.30 12.35 11.54 12.05
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -58 -64 -58 -49 -38
Operating Cash Flow to CapEx		 -4,938.12% -3,423.41% -5,178.83% -19,261.59% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.05 0.15 0.07 0.05 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 6.60 16.17 5.53 3.31 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -58 -24 -9.98 -4.76 2.61 -2.21
Invested Capital Turnover		 -0.16 -0.75 -0.91 -1.24 0.00 -0.19
Increase / (Decrease) in Invested Capital		 0.00 34 14 5.22 7.37 3.93
Enterprise Value (EV)		 168 218 -61 -79 -44 -58
Market Capitalization		 125 450 96 95 79 77
Book Value per Share		 ($36.54) $5.79 $4.05 $3.52 $2.61 $11.91
Tangible Book Value per Share		 ($36.54) $5.79 $4.05 $3.52 $2.61 $11.91
Total Capital		 105 208 147 171 127 133
Total Debt		 0.00 0.00 0.00 0.95 1.06 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.95 1.06 0.00
Net Debt		 -162 -232 -157 -175 -123 -135
Capital Expenditures (CapEx)		 0.77 1.76 1.43 0.41 -0.44 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -25 -23 -18 -11 -8.00 -6.30
Debt-free Net Working Capital (DFNWC)		 138 209 139 164 116 129
Net Working Capital (NWC)		 138 209 139 164 116 129
Net Nonoperating Expense (NNE)		 13 10 19 15 7.95 11
Net Nonoperating Obligations (NNO)		 -163 -232 -157 -175 -123 -135
Total Depreciation and Amortization (D&A)		 0.30 0.54 0.80 -1.00 -0.98 0.96
Debt-free, Cash-free Net Working Capital to Revenue		 -270.33% -73.87% -118.07% -120.17% 0.00% -786.88%
Debt-free Net Working Capital to Revenue		 1,497.03% 675.58% 886.84% 1,795.38% 0.00% 16,131.75%
Net Working Capital to Revenue		 1,497.03% 675.58% 886.84% 1,795.38% 0.00% 16,131.75%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.22) ($1.90) ($1.63) ($1.02) ($9.64)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 36.11M 36.19M 41.74M 48.26M 4.87M
Adjusted Diluted Earnings per Share		 $0.00 ($1.22) ($1.90) ($1.63) ($1.02) ($9.64)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 36.11M 36.19M 41.74M 48.26M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.22) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 27.98M 36.26M 48.26M 48.26M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -24 -50 -53 -38 -34
Normalized NOPAT Margin		 -338.95% -77.12% -317.79% -576.33% 0.00% -4,239.46%
Pre Tax Income Margin		 -481.36% -110.03% -440.29% -745.94% 0.00% -5,712.38%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.97% 0.00% 0.00%

Quarterly Metrics And Ratios for ImageneBio

This table displays calculated financial ratios and metrics derived from ImageneBio's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 42,301,253.00 48,258,111.00 48,258,111.00 48,258,111.00 48,258,111.00 - 48,258,111.00 48,258,111.00 48,258,111.00 11,181,672.00 11,181,672.00
DEI Adjusted Shares Outstanding		 3,525,104.00 4,021,509.00 4,021,509.00 4,021,509.00 4,021,509.00 - 4,021,509.00 4,021,509.00 4,021,509.00 11,181,672.00 11,181,672.00
DEI Earnings Per Adjusted Shares Outstanding		 -4.92 -4.85 -4.01 -3.41 -1.54 - -2.27 -0.69 -6.37 -1.38 -0.95
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -81.49% -87.93% -100.00% -100.00% 195.36% 0.00% 0.00% 0.00% -100.00% 0.00% -100.00%
EBITDA Growth		 -12.47% -47.13% -16.40% 15.57% 93.49% 50.60% 67.84% 74.86% -1,778.31% -4,008.37% -95.46%
EBIT Growth		 -9.04% -45.53% -17.52% 15.72% 83.45% 51.47% 67.09% 74.07% -666.71% -7,476.86% -95.63%
NOPAT Growth		 -9.10% -44.95% -17.47% 14.42% 89.56% 42.87% 67.11% 44.70% -1,206.19% -152.79% -101.48%
Net Income Growth		 -0.03% -38.25% -13.55% 19.78% 81.65% 53.18% 62.36% 79.85% -678.48% -161.73% -74.74%
EPS Growth		 16.67% -5.26% 15.38% 36.36% 81.65% 50.00% 62.36% 78.57% -12.79% 13.19% 75.00%
Operating Cash Flow Growth		 -16.13% -23.59% 7.48% 31.09% 164.82% 71.31% 60.50% 72.63% -305.54% -107.71% -104.70%
Free Cash Flow Firm Growth		 48.62% 17.59% 50.72% 70.34% 67.95% 21.54% 23.25% -217.15% -201.80% -844.88% 0.21%
Invested Capital Growth		 42.90% 52.32% 28.27% -318.30% 57.25% 154.83% 309.74% 891.60% 27.62% 64.03% 45.73%
Revenue Q/Q Growth		 -40.87% -44.47% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 -5.22% -10.54% 16.07% 13.51% 91.89% 11.70% -2,853.49% 60.45% -505.92% 65.35% -37.70%
EBIT Q/Q Growth		 -5.46% -12.40% 16.83% 14.51% 79.29% 11.30% -5,058.68% 59.62% -512.49% 63.95% -31.50%
NOPAT Q/Q Growth		 -5.48% -12.34% 16.81% 13.18% 87.13% -0.89% -555.19% 18.94% -203.93% 91.30% -422.22%
Net Income Q/Q Growth		 -1.33% -12.37% 17.15% 14.96% 76.82% 10.85% -73.18% 67.90% -795.52% 62.94% -15.63%
EPS Q/Q Growth		 9.09% 0.00% 17.50% 15.15% 76.82% 4.76% -73.18% 66.67% -4,750.00% -8.59% 69.94%
Operating Cash Flow Q/Q Growth		 -10.22% -9.11% 16.11% 31.70% 203.68% 29.96% -108.06% 67.60% -678.55% 72.91% -105.04%
Free Cash Flow Firm Q/Q Growth		 33.93% -1.10% 34.10% 32.62% 28.61% -17.08% -1,494.70% -110.44% 32.07% 71.76% -86.84%
Invested Capital Q/Q Growth		 -1,352.94% 46.49% 57.92% -27.87% -48.48% 168.64% 168.34% 382.61% -113.58% 19.67% 376.88%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 0.00% 100.00% 0.00% 100.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 -1,674.26% -3,333.13% 0.00% 0.00% -36.89% 0.00% -740.00% 0.00% 0.00% -1,050.38% 0.00%
Operating Margin		 -1,645.82% -3,329.64% 0.00% 0.00% -58.17% 0.00% -749.38% 0.00% 0.00% -289.13% 0.00%
EBIT Margin		 -1,645.99% -3,331.76% 0.00% 0.00% -92.26% 0.00% -750.00% 0.00% 0.00% -1,115.75% 0.00%
Profit (Net Income) Margin		 -1,463.54% -2,961.85% 0.00% 0.00% -90.94% 0.00% -759.63% 0.00% 0.00% -1,148.00% 0.00%
Tax Burden Percent		 100.00% 99.18% 100.17% 100.45% 100.00% 100.58% 100.00% 100.55% 99.70% 96.64% 100.09%
Interest Burden Percent		 88.92% 89.64% 88.41% 87.68% 98.58% 85.26% 101.28% 68.09% 100.39% 106.46% 90.38%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,053.36% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,051.98% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,035.50% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -36.29% -43.04% -48.28% -44.54% -32.70% -33.30% -17.86% -23.76% -38.20% -68.91% -41.30%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,864.63% -560.59% -266.24% 0.00% 0.00% -777.18%
Operating Return on Assets (OROA)		 -113.18% -167.53% 0.00% 0.00% -2.11% 0.00% -21.24% 0.00% 0.00% -10.57% 0.00%
Return on Assets (ROA)		 -100.64% -148.93% 0.00% 0.00% -2.08% 0.00% -21.52% 0.00% 0.00% -10.88% 0.00%
Return on Common Equity (ROCE)		 -32.95% -43.04% -48.28% -44.54% -29.46% -33.30% -17.86% -23.76% -38.20% 24.29% -41.30%
Return on Equity Simple (ROE_SIMPLE)		 -40.41% 0.00% -45.12% -46.70% 0.00% 0.00% 0.00% -26.52% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -15 -13 -11 -1.43 -8.76 -4.20 -6.13 -19 -1.62 -8.46
NOPAT Margin		 -1,152.08% -2,330.74% 0.00% 0.00% -40.72% 0.00% -524.56% 0.00% 0.00% -202.39% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.99% -2.51% -2.30% -1.75% -1.05% -0.24% -1.39% 2.79% -4.39% -10.81% -1.87%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.98% -8.21% -7.75% -1.06% -6.90% -3.55% -5.28% -13.31% -1.22% -6.86%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 509.20% 1,260.33% 0.00% 0.00% 47.17% 0.00% 344.38% 0.00% 0.00% -46.25% 0.00%
R&D to Revenue		 1,236.62% 2,169.30% 0.00% 0.00% 111.00% 0.00% 505.00% 0.00% 0.00% 653.38% 0.00%
Operating Expenses to Revenue		 1,745.82% 3,429.64% 0.00% 0.00% 158.17% 0.00% 849.38% 0.00% 0.00% 389.13% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 -22 -18 -16 -3.23 -11 -6.00 -4.04 -25 -8.93 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -22 -18 -16 -1.29 -11 -5.92 -4.00 -24 -8.40 -12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.18 0.56 0.44 0.56 0.62 0.63 0.52 0.56 0.23 0.58 0.45
Price to Tangible Book Value (P/TBV)		 1.18 0.56 0.44 0.56 0.62 0.63 0.52 0.56 0.23 0.58 0.45
Price to Revenue (P/Rev)		 13.13 10.38 17.81 43.20 20.08 0.00 14.37 0.00 0.00 96.44 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -1.05 -1.02 -1.01 -1.04 -1.01 -0.99 -0.93 -1.02 -1.06 -0.96
Leverage Ratio		 1.17 1.15 1.12 1.10 1.13 1.13 1.11 1.10 1.13 1.28 1.11
Compound Leverage Factor		 1.04 1.03 0.99 0.96 1.12 0.96 1.12 0.75 1.14 1.37 1.00
Debt to Total Capital		 0.45% 0.56% 0.00% 0.00% 0.00% 0.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.45% 0.56% 0.00% 0.00% 0.00% 0.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 16.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 82.61% 99.44% 100.00% 100.00% 100.00% 99.16% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.01 -0.01 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 2.82 2.28 0.00 0.00 0.00 2.15 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.01 -0.01 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.02 -0.02 0.00 0.00 0.00 -0.03 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 4.08 3.31 0.00 0.00 0.00 2.99 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.02 -0.02 0.00 0.00 0.00 -0.03 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.97 1.19 0.66 1.25 1.39 0.51 0.18 0.74 -0.52 1.05 0.78
Noncontrolling Interest Sharing Ratio		 9.20% 0.00% 0.00% 0.00% 9.91% 0.00% 0.00% 0.00% 0.00% 135.25% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.41 12.58 15.85 18.22 15.32 11.80 13.31 13.52 13.24 12.49 18.39
Quick Ratio		 10.22 12.35 15.47 17.74 14.94 11.54 12.97 13.06 12.79 12.05 17.67
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 -21 -14 -9.13 -6.52 -16 -10 -29 -20 -5.55 -10
Operating Cash Flow to CapEx		 0.00% -8,202.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.05 0.02 0.01 0.02 0.00 0.03 0.00 0.00 0.01 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.85 3.31 1.93 1.01 2.51 0.00 6.28 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.89 -4.76 -2.00 -2.56 -3.80 2.61 4.20 20 -2.75 -2.21 6.12
Invested Capital Turnover		 -1.14 -1.24 -1.61 -1.16 -0.66 0.00 3.91 0.00 0.00 -0.19 0.00
Increase / (Decrease) in Invested Capital		 6.68 5.22 0.79 -1.95 5.09 7.37 6.20 23 1.05 3.93 1.92
Enterprise Value (EV)		 19 -79 -89 -66 -55 -44 -52 -31 -110 -58 -61
Market Capitalization		 183 95 69 80 83 79 62 65 33 77 56
Book Value per Share		 $3.67 $3.52 $3.22 $2.96 $2.78 $2.61 $2.45 $2.40 $2.90 $11.91 $5.50
Tangible Book Value per Share		 $3.67 $3.52 $3.22 $2.96 $2.78 $2.61 $2.45 $2.40 $2.90 $11.91 $5.50
Total Capital		 188 171 155 143 134 127 118 116 140 133 123
Total Debt		 0.85 0.95 0.00 0.00 0.00 1.06 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.85 0.95 0.00 0.00 0.00 1.06 0.00 0.00 0.00 0.00 0.00
Net Debt		 -196 -175 -157 -145 -138 -123 -114 -96 -143 -135 -117
Capital Expenditures (CapEx)		 0.00 0.27 -0.06 -0.19 -0.62 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -11 -6.35 -4.29 -5.74 -8.00 -5.85 -3.95 -6.20 -6.30 -1.84
Debt-free Net Working Capital (DFNWC)		 181 164 151 141 132 116 108 92 136 129 115
Net Working Capital (NWC)		 181 164 151 141 132 116 108 92 136 129 115
Net Nonoperating Expense (NNE)		 3.69 4.15 3.39 2.65 1.76 0.36 1.88 -3.36 6.16 7.56 2.16
Net Nonoperating Obligations (NNO)		 -196 -175 -157 -145 -138 -123 -114 -96 -143 -135 -117
Total Depreciation and Amortization (D&A)		 -0.34 -0.01 -0.17 -0.33 1.94 -0.20 0.08 0.04 0.51 0.52 0.17
Debt-free, Cash-free Net Working Capital to Revenue		 -111.60% -120.17% -165.12% -232.99% -138.05% 0.00% -135.93% 0.00% 0.00% -786.88% 0.00%
Debt-free Net Working Capital to Revenue		 1,299.91% 1,795.38% 3,925.06% 7,657.35% 3,181.65% 0.00% 2,516.42% 0.00% 0.00% 16,131.75% 0.00%
Net Working Capital to Revenue		 1,299.91% 1,795.38% 3,925.06% 7,657.35% 3,181.65% 0.00% 2,516.42% 0.00% 0.00% 16,131.75% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.40) ($0.40) ($0.33) ($0.28) ($2.52) ($0.20) ($2.16) ($0.06) ($2.91) ($3.16) ($0.95)
Adjusted Weighted Average Basic Shares Outstanding		 43.44M 41.74M 48.26M 48.26M 4.02M 48.26M 4.02M 48.26M 8.53M 4.87M 22.42M
Adjusted Diluted Earnings per Share		 ($0.40) ($0.40) ($0.33) ($0.28) ($2.52) ($0.20) ($2.16) ($0.06) ($2.91) ($3.16) ($0.95)
Adjusted Weighted Average Diluted Shares Outstanding		 43.44M 41.74M 48.26M 48.26M 4.02M 48.26M 4.02M 48.26M 0.00 0.00 22.42M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.16) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 48.26M 48.26M 48.26M 48.26M 4.02M 48.26M 4.02M 48.26M 11.18M 0.00 11.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -15 -11 -11 -1.43 -8.52 -4.20 -5.91 -19 -1.62 -8.46
Normalized NOPAT Margin		 -1,152.08% -2,330.74% 0.00% 0.00% -40.72% 0.00% -524.56% 0.00% 0.00% -202.39% 0.00%
Pre Tax Income Margin		 -1,463.54% -2,986.47% 0.00% 0.00% -90.94% 0.00% -759.63% 0.00% 0.00% -1,187.88% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.06% -0.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ImageneBio (NASDAQ: IMA) is still operating like a development-stage biotech: no meaningful product revenue in the latest quarter, recurring losses, and continued cash burn. The good news is that the company ended Q1 2026 with a very strong cash position, which gives it some runway. The less encouraging part is that operations are still deeply unprofitable, and the company has relied on financing and investment activity to support liquidity.

Here are the key takeaways from the last several quarters:

  • Strong liquidity remains the biggest positive: Q1 2026 ended with $76.0 million in cash and $41.2 million in short-term investments, for roughly $117.2 million in liquid resources.
  • Balance sheet improved versus a year ago: Total liabilities fell to $13.4 million in Q1 2026 from $12.6 million in Q1 2025 and were well below the company’s asset base, leaving equity at $123.3 million.
  • Investment portfolio still helps support cash: The company continues to manage its treasury through purchases and maturities of investments, which helped offset some operating burn in prior periods.
  • Common stock equity remains large relative to liabilities: Book equity was positive at $123.3 million, which suggests the balance sheet is not stressed by leverage.
  • Operating expenses remain the main issue: In Q1 2026, SG&A was $6.1 million and R&D was $6.0 million, for total operating expenses of $12.1 million against zero revenue.
  • Other income is helping, but it is not core revenue: Q1 2026 had $1.47 million of other income, including $1.13 million of interest and investment income.
  • Still no operating revenue in the latest quarter: Q1 2026 reported $0 revenue, compared with modest revenue in some earlier quarters, underscoring the early-stage nature of the business.
  • Quarterly losses remain significant: Q1 2026 net loss was $10.6 million, after a $9.2 million loss in Q4 2025 and a $27.8 million loss in Q3 2025.
  • Operating cash flow is consistently negative: Q1 2026 burned $14.8 million in operating activities, following negative operating cash flow in each of the last several quarters.
  • Share count has been volatile and dilution has been a concern: The company issued common equity in 2025, and weighted average shares changed sharply across periods, which can pressure per-share results for investors.

Looking at the trend, ImageneBio’s financial profile improved on the liquidity side, but not on the operating side. Cash and investments are high enough to fund the business in the near term, yet the company is still spending heavily on R&D and general overhead without product sales to offset those costs.

For retail investors, the main question is whether ImageneBio can turn its cash cushion into meaningful clinical or strategic progress before the balance sheet starts shrinking faster. Until revenue becomes more durable, the stock will likely remain driven by pipeline news, financing risk, and sentiment around biotech execution.

07/14/26 06:12 AM ETAI Generated. May Contain Errors.

ImageneBio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ImageneBio's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ImageneBio's net income were at -$45.35 million at the end of 2025, a 24.0% increase from 2024, and a 2.5% increase since 2020. View ImageneBio's forecast to see where analysts expect ImageneBio to go next.

ImageneBio's total operating income in 2025 was -$48.45 million, based on the following breakdown:
  • Total Gross Profit: $800 thousand
  • Total Operating Expenses: $49.25 million

Over the last 5 years, ImageneBio's total revenue changed from $9.19 million in 2020 to $800 thousand in 2025, a change of -91.3%.

ImageneBio's total liabilities were at $19.84 million at the end of 2025, a 13.7% increase from 2024, and a 68.7% decrease since 2020.

In the past 5 years, ImageneBio's cash and equivalents has ranged from $12.12 million in 2024 to $232.22 million in 2021, and is currently $94.53 million as of their latest financial filing in 2025.

Over the last 5 years, ImageneBio's book value per share changed from -36.54 in 2020 to 11.91 in 2025, a change of -132.6%.


Related Companies

Financial statements for NASDAQ:IMA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your money is changing
Porter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...
Porter & Company | Sponsoredtc pixel
The $5 company SpaceX can’t survive without
The investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...
Traders Agency | Sponsoredtc pixel
Trump Set to Unleash 219-Year-Old “Super Weapon” on U.S. Soil
Four-time U.S. Presidential advisor Jim Rickards is warning of a political move he calls 'The Trump Supremacy'...
Paradigm Press | Sponsoredtc pixel
60 years. Zero competitors.
One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...
Behind the Markets | Sponsoredtc pixel